Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
/PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) today announced new data from its ongoing Phase 2 REVIVE study evaluating rusfertide in patients with...
United States Ronald Hoffman Dineshv Patel Icahn School Of Medicine At Mount Sinai American Society Of Clinical Oncology Tisch Cancer Institute
Source: prnewswire.com